A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial
About this study
The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are: O1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local/locally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer
- Condition
- Pelvic Fracture, Prostate Cancer, Lung Cancer, Brain Metastasis, Chronic Subdural Hematoma
- Tested
- Test set to determine vulnerability
- Sponsor
- Tampere University Hospital
Who can join
- Age
- Not specified
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 8
- Eligible sex: Male
- Study condition: Pelvic Fracture, Prostate Cancer, Lung Cancer, Brain Metastasis, Chronic Subdural Hematoma
- Suspected or diagnosed disease
- ≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old
- Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line
- Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line
- Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment
- Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization
Exclusion 2
- Not willing or unable to give written consent
- Patient not deemed suitable for the study by the researcher approaching the patient
Where
1 site, 1 recruiting
Tampere University Hospital
Tampere, Finland
Contact
-
Otso Arponen, Adjunct professor, MD
504106170 otso.arponen@tuni.fi
Potential match only. Final eligibility is determined by the study team.